Enzalutamide (XTANDI) is a prescription medicine used to treat men with prostate cancer that no longer responds to a medical or surgical treatment that lowers testosterone. XTANDI is now approved to treat men with prostate cancer that no longer responds to treatment that lowers testosterone and has not spread to other parts of the body. This is also known as non-metastatic castration-resistant prostate cancer (CRPC).
This web page, published by the National Cancer Institute, lists the clinical trials using Enzalutamide. Click here to view the article.